4.6 Article

In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor

Journal

PLOS ONE
Volume 7, Issue 5, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0037508

Keywords

-

Funding

  1. Institut National de la Sante et de la Recherche Medicale
  2. Laboratoires Francais de Fractionnement et des Biotechnologies (LFB)
  3. Agence Nationale de la Recherche [ANR-08-CEXC-018-01]
  4. Groupe d'Etude sur l'Hemostase et la Thrombose
  5. Societe Francaise d'Hematologie

Ask authors/readers for more resources

The objective of this project was to study the function of O-glycosylations in von Willebrand factor (VWF) life cycle. In total, 14 different murine Vwf cDNAs mutated on one or several O-glycosylations sites were generated: 9 individual mutants, 2 doublets, 2 clusters and 1 mutant with all 9 murine glycosylation sites mutated (Del-O-Gly). We expressed each mutated cDNA in VWF deficient-mice by hydrodynamic injection. An immunosorbent assay with Peanut Agglutinin (PNA) was used to verify the O-glycosylation status. Wild-type (WT) VWF expressed by hepatocytes after hydrodynamic injection was able to bind PNA with slightly higher affinity than endothelial-derived VWF. In contrast, the Del-O-Gly VWF mutant did not bind PNA, demonstrating removal of O-linked glycans. All mutants displayed a normal multimeric pattern. Two mutants, Del-OGly and T1255A/T1256A, led to expression levels 50% lower than those induced by WT VWF and their half-life in vivo was significantly reduced. When testing the capacity of each mutant to correct the bleeding time of VWF-deficient mice, we found that S1486A, T1255A, T1256A and the doublet T1255A/T1256A were unable to do so. In conclusion we have shown that O-glycosylations are dispensable for normal VWF multimerization and biosynthesis. It also appears that some O-glycosylation sites, particularly the T1255 and T1256 residues, are involved in the maintenance of VWF plasma levels and are essential for normal haemostasis. As for the S1486 residue, it seems to be important for platelet binding as demonstrated in vitro using perfusion experiments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor

Elena Barbon, Charlotte Kawecki, Solenne Marmier, Aboud Sakkal, Fanny Collaud, Severine Charles, Giuseppe Ronzitti, Caterina Casari, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Federico Mingozzi

Summary: Von Willebrand disease (VWD), the most common inherited bleeding disorder, has limited efficacy with current liver-directed gene therapy. This study developed a gene therapy strategy using an optimized AAV vector and endothelial-targeting peptide to deliver the VWF gene into endothelial cells, achieving long-term expression.

GENE THERAPY (2023)

Article Gastroenterology & Hepatology

In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model

Eleanor Luce, Clara Steichen, Mickael Allouche, Antonietta Messina, Jean-Marie Heslan, Thierry Lambert, Anne Weber, Tuan Huy Nguyen, Olivier Christophe, Anne Dubart-Kupperschmitt

Summary: Assessing differentiation of induced pluripotent stem cells from hemophilia B patients based on the production and activity of coagulation factor IX reveals the importance of mature hepatocytes for functional recovery in transplantation.

HEPATOLOGY (2022)

Article Immunology

SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation

Rachel E. Lamerton, Edith Marcial-Juarez, Sian E. Faustini, Marisol Perez-Toledo, Margaret Goodall, Sian E. Jossi, Maddy L. Newby, Iain Chapple, Thomas Dietrich, Tonny Veenith, Adrian M. Shields, Lorraine Harper, Ian R. Henderson, Julie Rayes, David C. Wraith, Steve P. Watson, Max Crispin, Mark T. Drayson, Alex G. Richter, Adam F. Cunningham

Summary: This study investigates the interaction between SARS-CoV-2 antibodies and complement activation using an ELISA assay. The results suggest that the downstream effects of antibody-dependent complement activation may vary depending on the disease status and the specific antigen targeted.

FRONTIERS IN IMMUNOLOGY (2022)

Article Hematology

A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

Claire Kizlik-Masson, Ivan Peyron, Stephane Gangnard, Gaelle Le Goff, Solen M. Lenoir, Sandra Damodaran, Marie Clavel, Stephanie Roullet, Veronique Regnault, Antoine Rauch, Flavien Vincent, Emmanuelle Jeanpierre, Annabelle Dupont, Catherine Ternisien, Thibault Donnet, Olivier D. Christophe, Eric van Belle, Cecile Denis, Caterina Casari, Sophie Susen, Peter J. Lenting

Summary: A nanobody (KB-VWF-D3.1) is identified to distinguish proteolyzed and non-proteolyzed VWF and monitor VWF degradation levels. Reduced intact-VWF levels are observed in patients with von Willebrand disease, aortic stenosis, and patients receiving mechanical circulatory support.

BLOOD (2023)

Article Oncology

Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Abdullah O. Khan, Antonio Rodriguez-Romera, Jasmeet S. Reyat, Aude-Anais Olijnik, Michela Colombo, Guanlin Wang, Wei Xiong Wen, Nikolaos Sousos, Lauren C. Murphy, Beata Grygielska, Gina Perrella, Christopher B. Mahony, Rebecca E. Ling, Natalina E. Elliott, Christina Simoglou Karali, Andrew P. Stone, Samuel Kemble, Emily A. Cutler, Adele K. Fielding, Adam P. Croft, David Bassett, Gowsihan Poologasundarampillai, Anindita Roy, Sarah Gooding, Julie Rayes, Kellie R. Machlus, Bethan Psaila

Summary: This study presents a human bone marrow organoid that can support the growth and survival of primary cells from patients with myeloid and lymphoid blood cancers. This organoid model allows for mechanistic studies of blood cancers within their microenvironment and serves as an ex vivo tool for prioritizing new therapeutics.

CANCER DISCOVERY (2023)

Review Hematology

Basic Mechanisms of Hemolysis-Associated Thrombo-Inflammation and Immune Dysregulation

Jordan D. D. Dimitrov, Lubka T. T. Roumenina, Gina Perrella, Julie Rayes

Summary: Regardless of the cause, hemolytic diseases are associated with thrombosis, inflammation, and immune dysregulation, resulting in organ damage and poor outcomes. Hemolysis not only leads to anemia and loss of the anti-inflammatory functions of red blood cells, but also releases damage-associated molecular patterns, such as ADP, hemoglobin, and heme, which trigger a hyperinflammatory and hypercoagulable state through various receptors and signaling pathways. Extracellular free heme, in particular, can activate platelets, endothelial cells, innate cells, as well as the coagulation and complement cascades, thereby promoting thrombo-inflammatory events. This review discusses the main mechanisms by which hemolysis, especially heme, drives this thrombo-inflammatory environment and explores the impact of hemolysis on the host response to secondary infections.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Article Hematology

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models

Stephanie Roullet, Norman Luc, Julie Rayes, Jean Solarz, Dante Disharoon, Andrew Ditto, Emily Gahagan, Christa Pawlowski, Thibaud Sefiane, Frederic Adam, Caterina Casari, Olivier D. Christophe, Michael Bruckman, Peter J. Lenting, Anirban Sen Gupta, Cecile Denis

Summary: The lack of innovation in von Willebrand disease (VWD) is due to the complexity and heterogeneity of the disease and a lack of recognition of the impact of bleeding symptoms experienced by patients. This study proposes a new approach using synthetic platelet (SP) nanoparticles for the treatment of VWD-2B and severe VWD. The results show that SP can improve thrombus formation and reduce blood loss in VWD-2B and VWF-KO mice.

BLOOD (2023)

Article Cardiac & Cardiovascular Systems

Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia

Antoine Rauch, Annabelle Dupont, Mickael Rosa, Maximilien Desvages, Christina Le Tanno, Johan Abdoul, Melusine Didelot, Alexandre Ung, Richard Ruez, Emmanuelle Jeanpierre, Melanie Daniel, Delphine Corseaux, Hugues Spillemaeker, Julien Labreuche, Benedicte Pradines, Natacha Rousse, Peter J. Lenting, Mouhamed D. Moussa, Andre Vincentelli, Jean-Claude Bordet, Bart Staels, Flavien Vincent, Cecile V. Denis, Eric Van Belle, Caterina Casari, Sophie Susen

Summary: Thrombocytopenia is consistently observed in ECMO patients, with a time-dependent decrease in platelet count, GP Ib alpha shedding, and increased soluble GP Ib alpha levels. Shedding of GP Ib alpha is dependent on rheological conditions, with higher rates at high-flow speeds.

CIRCULATION RESEARCH (2023)

Article Hematology

Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor

Alexis Texier, Peter J. Lenting, Cecile Denis, Stephanie Roullet, Olivier D. Christophe

Summary: This study reveals the binding between von Willebrand factor and angiopoietin-2, with angiopoietin-2 enhancing the binding of von Willebrand factor to angiopoietin-1.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation

Alexandre Kauskot, Coralie Mallebranche, Arnaud Bruneel, Francois Fenaille, Jean Solarz, Toscane Viellard, Miao Feng, Christelle Reperant, Jean-Claude Bordet, Sophie Cholet, Cecile Denis, Genevieve McCluskey, Sylvain Latour, Emmanuel Martin, Isabelle Pellier, Dominique Lasne, Delphine Borgel, Sven Kracker, Alban Ziegler, Marie Tuffigo, Benjamin Fournier, Charline Miot, Frederic Adam

Summary: XMEN disease, caused by loss-of-function mutations in the MAGT1 gene, is associated with platelet dysfunction and defective N-glycosylation, which may explain the bleeding events in patients with XMEN disease.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab

Melissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, Ivan Peyron, Ladislas Capdevila, Victoria Daventure, Claire Deligne, Jordan D. Dimitrov, Olivier D. Christophe, Cecile V. Denis, Peter J. Lenting, Valerie Proulle, Sebastien Lacroix-Desmazes

Summary: This study investigated the impact of IdeS treatment in inhibitor-positive HA mice injected with emicizumab. The results showed that IdeS efficiently eliminated anti-FVIII IgG and restored the hemostatic efficacy of exogenous FVIII, unaffected by the presence of emicizumab and polyclonal human IgG in the mice.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

No Data Available